Skip to main content
. Author manuscript; available in PMC: 2015 Mar 24.
Published in final edited form as: Cancer. 2011 Mar 31;117(20):4679–4688. doi: 10.1002/cncr.26091

Figure 1.

Figure 1

(A) Overall survival (OS)and current progression-free survival rates of 86 chronic lymphocytic leukemia patients who underwent nonmyeloablative stem cell transplantation are shown. OS is shown (B) according to CD4/mm3 and immunoglobulin G (IgG) levels at the time of study entry, (C) according to the hematopoietic stem cell transplantation comorbidity-index, and (D) according to age (< or 60 years).